Sofia Ajeganova | Karolinska Institutet

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: LANCET RHEUMATOLOGY. 2026;8(3):e192-e203
Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries
Bolla E; Semb AG; Petri M; Sfikakis PP; Artim-Esen B; Hernandez-Molina G; Hachulla E; Direskeneli H; Karpouzas GA; Zucchi D; Goyal M; Costedoat-Chalumeau N; Tincani A; Yazici A; Lerang K; Troldborg A; Ajeganova S; Popkova TV; Svenungsson E; Pantazis N; Tektonidou MG
Article: ANNALS OF THE RHEUMATIC DISEASES. 2026;85(3):425-434
Inflammation rather than anticitrullinated protein antibodies is associated with cardiovascular mortality in RA: insights from rheumatoid arthritis and coronary artery disease cohorts.
Derksen VFAM; Lindschou J; Winkel P; Delgado GE; de Moel EC; Huizinga TWJ; März W; Jakobsen JC; van der Helm-Van Mil AHM; Toes REM; Ajeganova S; Gluud C; Leipe J; van der Woude D; CLARICOR Trial Group and the LURIC Study Group
Article: RMD OPEN. 2025;11(3):e005784
The equivocal opposite effects of lower and higher body mass index at diagnosis on radiographic joint damage progression in early rheumatoid arthritis: an inception cohort study over 15 years
Ajeganova S; Forslind K; Hafstrom I
Article: NEUROLOGY. 2025;104(5):e213405
Association of Rheumatoid Arthritis With Progression of Cognitive Impairment and Risk of Mortality in People With Dementia
Mo M; Eriksdotter M; Ajeganova S; Mitra S; Garcia-Ptacek S; Xu H
Article: RMD OPEN. 2025;11(1):e004744
Persistently different patterns of patient's global assessment of health in rheumatoid arthritis are associated with pain and impaired function more than with inflammation: an inception cohort study over 15 years
Bala V; Hafstrom I; Svensson B; Ajeganova S
Article: RMD OPEN. 2024;10(3):e004535
Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial
Bertrand D; Joly J; Neerinckx B; Durez P; Lenaerts J; Joos R; Thevissen K; Zwaenepoel T; Vanhoof J; Di Romana S; Taelman V; Van Essche E; Corluy L; Ribbens C; Vanden Berghe M; Devinck M; Ajeganova S; Durnez A; Boutsen Y; Margaux J; Peene I; Van Offel J; Doumen M; Pazmino S; De Meyst E; Kulyk M; Creten N; Westhovens R; Verschueren P
Article: LANCET RHEUMATOLOGY. 2024;6(7):e447-e459
Prevalence and target attainment oftraditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
Bolla E; Semb AG; Kerola AM; Ikdahl E; Petri M; Pons-Estel GJ; Karpouzas GA; Sfikakis PP; Quintana R; Misra DP; Borba EF; Torre IG-DL; Popkova TV; Artim-Esen B; Troldborg A; Fragoso-Loyo H; Ajeganova S; Yazici A; Aroca-Martinez G; Direskeneli H; Ugarte-Gil MF; Mosca M; Goyal M; Svenungsson E; Macieira C; Hoi A; Lerang K; Costedoat-Chalumeau N; Tincani A; Mirrakhimov E; Colman IA; Danza A; Massardo L; Blagojevic J; Yilmaz N; Tegzova D; Yavuz S; Korkmaz C; Hachulla E; Alvarez MJM; Munoz-Louis R; Pantazis N; Tektonidou MG
Article: BMC RHEUMATOLOGY. 2023;7(1):23
Long-term fracture risk in rheumatoid arthritis: impact of early sustained DAS28-remission and restored function, progressive erosive disease, body mass index, autoantibody positivity and glucocorticoids. A cohort study over 10 years
Ajeganova S; Andersson M; Forslind K; Gjertsson I; Nyhall-Wahlin B-M; Svensson B; Hafstrom I
Article: BMC RHEUMATOLOGY. 2022;6(1):88
Erosion-free rheumatoid arthritis: clinical and conceptional implications-a BARFOT study
Svensson B; Andersson MLE; Gjertsson I; Hafstroem I; Ajeganova S; Forslind K
Article: OPEN ACCESS RHEUMATOLOGY: RESEARCH AND REVIEWS. 2022;14:187-194
Misdiagnosis of Rheumatoid Arthritis in a Long-Term Cohort of Early Arthritis Based on the ACR-1987 Classification Criteria
Agelii ML; Hafstrom I; Svensson B; Ajeganova S; Forslind K; Andersson M; Gjertsson I
Article: ACR OPEN RHEUMATOLOGY. 2021;3(9):642-653
Effects of Atorvastatin on T-Cell Activation and Apoptosis in Systemic Lupus Erythematosus and Novel Simulated Interactions With C-Reactive Protein and Interleukin 6
Sun J; Panda PK; Samal SK; Ahuja R; Ajeganova S; Hafstrom I; Liu A; Frostegard J
Article: JOURNAL OF RHEUMATOLOGY. 2021;48(9):1371-1378
Team Rehabilitation in Inflammatory Arthritis Benefits Functional Outcomes Along With Improved Body Composition Associated With Improved Cardiorespiratory Fitness
Ajeganova S; Wornert M; Hafstrom I
Article: ARTHRITIS RESEARCH & THERAPY. 2021;23(1):201
Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events
Ajeganova S; Andersson MLE; Frostegard J; Hafstrom I
Article: OPEN ACCESS RHEUMATOLOGY: RESEARCH AND REVIEWS. 2021;13:123-138
Influence of Age and Sex on Disease Course and Treatment in Rheumatoid Arthritis
Nilsson J; Andersson MLE; Hafstrom I; Svensson B; Forslind K; Ajeganova S; Agelii ML; Gjertsson I
Article: LUPUS SCIENCE & MEDICINE. 2021;8(1):e000454
Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: a case-control study over 10 years
Ajeganova S; Hafstrom I; Frostegard J
Article: ARTHRITIS RESEARCH & THERAPY. 2021;23(1):32
Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-α: potential underlying mechanisms
Frostegard J; Ahmed S; Hafstrom I; Ajeganova S; Rahman M
Article: LUPUS. 2020;29(8):825-835
Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus
Liu A; Rahman M; Hafstrom I; Ajeganova S; Frostegard J
Article: ALLERGY. 2020;75(4):936-940
Biologicals in allergic diseases and asthma: Toward personalized medicine and precision health: Highlights of the 3rd EAACI Master Class on Biologicals, San Lorenzo de El Escorial, Madrid, 2019
Palomares O; Untersmayr E; Gutermuth J; Agache I; Ajeganova S; Bavbek S; Chan S; Jutel M; Quirce S; Schmid-Grendelmeier P; Schmidt-Weber C; Jose Torres M; Eiwegger T
Article: THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE. 2020;12:1759720X20974858
Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance
Ajeganova S; De Becker A; Schots R
Article: LUPUS SCIENCE & MEDICINE. 2020;7(1):e000362
Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients
Ajeganova S; Gustafsson T; Lindberg L; Hafstrom I; Frostegard J
Visa fler

Alla övriga publikationer

Editorial: ARTHRITIS & RHEUMATOLOGY. 2025;77(7):789-791
Air Pollution's Hidden Toll: Risks for Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Lung Disease
Ajeganova S; Sokolove J
Review: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2025;43(5):939-945
Acute coronary syndromes in young lupus patients, shifting the view on the old problem
Ajeganova S
Letter: ARTHRITIS & RHEUMATOLOGY. 2018;70(12):2096-2097
Anti-Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritis-A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al
Derksen VFAM; Westerlind H; Saevarsdottir S; Ajeganova S; Trouw LA; Huizinga TWJ; van der Helm-van Mil AHM; Knevel R; van der Woude D
Review: THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE. 2017;9(10):249-262
Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations
Ajeganova S; Huizinga T
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(7):e17
Disease-modifying treatment in rheumatoid arthritis: treat early and do not forget to try to taper and stop
Ajeganova S; van der Helm-van Mil AHM
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(4):e14-U5
Evaluation of the association between anticarbamylated protein antibodies and the longitudinal course of functional ability in rheumatoid arthritis
Ajeganova S; Svensson B; Huizinga TWJ; van der Helm-van Mil AHM; van Steenbergen HW
Editorial: NATURE REVIEWS RHEUMATOLOGY. 2015;11(1):8-9
Seronegative and seropositive RA: alike but different?
Ajeganova S; Huizinga TWJ
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(1):e3
The effects of rheumatoid factor and anticitrullinated peptide antibodies on bone erosions in rheumatoid arthritis
van Steenbergen HW; Ajeganova S; Forslind K; Svensson B; van der Helm-van Mil AHM
Letter: JOURNAL OF RHEUMATOLOGY. 2013;40(3):337-338
Prognosis Factors for Cardiovascular Events in Patients with Rheumatoid Arthritis: Multivariate Analysis Is Indispensable Reply
Ajeganova S; Hafstrom I
Doctoral thesis: 2012
Addressing cardiovascular risk factors and therapy effects in rheumatoid arthritis : implications for atherosclerosis and cardiovascular disease
Ajeganova S
Letter: ARTHRITIS & RHEUMATOLOGY. 2012;64(2):597
Alternative explanations for development of late-onset neutropenia in rituximab-treated rheumatic disease patients: comment on the article by Tesfa et al Reply
Tesfa D; Ajeganova S; Hafstrom I; Palmblad J

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2025-2028

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Huddinge, Karolinska Institutet, 2013

Nyheter från KI

Kalenderhändelser från KI